This Kinrix market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
The growth observed during the historic period can be attributed to factors such as the rising demand for combination vaccines, improved adherence to vaccination schedules, better resource utilization, the potential for broader disease protection, and a growing preference for patient convenience.
Looking ahead, the growth in the forecast period is driven by factors such as the increasing demand for fewer injections, a greater focus on preventive healthcare, enhanced international cooperation in vaccine development, a rising need for targeted therapies, and a surge in the demand for personalized medicines. Key trends expected in the forecast period include the development of needle-free vaccine options, advancements in drug delivery systems, the integration of digital technology in immunization, the use of blockchain for vaccine traceability, and AI-driven vaccine management.
The growing demand for combination vaccines is expected to drive the expansion of the kinrix market. A combination vaccine is a single shot that offers protection against multiple diseases by including antigens for two or more pathogens, thereby minimizing the number of injections required for immunization. The demand for these vaccines is increasing due to benefits such as wider vaccination coverage, reduced costs, improved compliance, and fewer injections. Kinrix is a combination vaccine used as a booster for children aged 4-6 years to protect against diphtheria, tetanus, pertussis, and poliovirus, reducing the need for multiple shots. For example, in September 2023, the National Health Service reported that in 2022-23, 91.79% of children received the DTaP/IPV/Hib/HepB (types of combination vaccines) by their first birthday. This growing demand for combination vaccines is a key driver for the kinrix market.
The increase in healthcare spending is expected to further fuel the growth of the kinrix market. Healthcare expenditure refers to the total financial resources spent on medical services, infrastructure, pharmaceuticals, and other healthcare activities. This spending is rising due to factors such as higher operational costs in healthcare facilities, the increasing prevalence of chronic and lifestyle-related diseases, the rise in genetic disorders, advances in medical technology, and better access to healthcare services. Higher healthcare spending helps improve access to Kinrix, supports greater immunization rates, and reduces disease burden. For instance, in May 2024, a report by the Office for National Statistics revealed that total healthcare spending rose by 5.6% from 2022 to 2023, compared to a 0.9% increase in 2022. Additionally, long-term health and social care spending increased by 2.8% in real terms in 2022. Therefore, the rise in healthcare expenditure is contributing to the growth of the kinrix market.
In May 2024, GlaxoSmithKline plc, a UK-based pharmaceutical company, partnered with the Department of Health, Abu Dhabi (DoH), to establish a regional vaccine distribution hub in Abu Dhabi. This collaboration, formalized through a Memorandum of Understanding (MoU), aims to improve healthcare innovation and vaccine accessibility across the region. The Department of Health-Abu Dhabi (DoH) is a UAE-based government agency focused on promoting healthy living standards and raising awareness among the residents of the UAE.
The key company operating in the kinrix market is GlaxoSmithKline plc.
North America was the largest region in the kinrix market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in kinrix report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the kinrix market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Kinrix is a combination vaccine that offers protection against four diseases, diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis (polio). It includes diphtheria and tetanus toxoids, an acellular pertussis vaccine (DTaP), and an inactivated poliovirus vaccine (IPV). This vaccine streamlines vaccination schedules by reducing the number of injections needed, ensuring ongoing protection against these serious diseases in a convenient and efficient manner.
The primary types of indications for Kinrix include vaccination against diphtheria, tetanus, pertussis, and poliomyelitis. To protect against diphtheria, a toxoid vaccine is administered to stimulate immunity and prevent severe respiratory infections caused by Corynebacterium diphtheriae. The vaccine is available in injectable formulations and pre-filled syringes, suitable for both pediatric and adult patients. It is distributed through direct sales, wholesalers, distributors, retail pharmacies, and online pharmacies. Various end users, including pediatric clinics, hospitals, family practice clinics, and public health departments, utilize this vaccine.
The kinrix market research report is one of a series of new reports that provides kinrix market statistics, including kinrix industry global market size, regional shares, competitors with a kinrix market share, detailed kinrix market segments, market trends and opportunities, and any further data you may need to thrive in the kinrix industry. This kinrix market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The kinrix market consists of sales of pre-filled syringes or single-dose vials of kinrix (DTaP-IPV). Values in this market are ‘factory gate’ values, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth observed during the historic period can be attributed to factors such as the rising demand for combination vaccines, improved adherence to vaccination schedules, better resource utilization, the potential for broader disease protection, and a growing preference for patient convenience.
Looking ahead, the growth in the forecast period is driven by factors such as the increasing demand for fewer injections, a greater focus on preventive healthcare, enhanced international cooperation in vaccine development, a rising need for targeted therapies, and a surge in the demand for personalized medicines. Key trends expected in the forecast period include the development of needle-free vaccine options, advancements in drug delivery systems, the integration of digital technology in immunization, the use of blockchain for vaccine traceability, and AI-driven vaccine management.
The growing demand for combination vaccines is expected to drive the expansion of the kinrix market. A combination vaccine is a single shot that offers protection against multiple diseases by including antigens for two or more pathogens, thereby minimizing the number of injections required for immunization. The demand for these vaccines is increasing due to benefits such as wider vaccination coverage, reduced costs, improved compliance, and fewer injections. Kinrix is a combination vaccine used as a booster for children aged 4-6 years to protect against diphtheria, tetanus, pertussis, and poliovirus, reducing the need for multiple shots. For example, in September 2023, the National Health Service reported that in 2022-23, 91.79% of children received the DTaP/IPV/Hib/HepB (types of combination vaccines) by their first birthday. This growing demand for combination vaccines is a key driver for the kinrix market.
The increase in healthcare spending is expected to further fuel the growth of the kinrix market. Healthcare expenditure refers to the total financial resources spent on medical services, infrastructure, pharmaceuticals, and other healthcare activities. This spending is rising due to factors such as higher operational costs in healthcare facilities, the increasing prevalence of chronic and lifestyle-related diseases, the rise in genetic disorders, advances in medical technology, and better access to healthcare services. Higher healthcare spending helps improve access to Kinrix, supports greater immunization rates, and reduces disease burden. For instance, in May 2024, a report by the Office for National Statistics revealed that total healthcare spending rose by 5.6% from 2022 to 2023, compared to a 0.9% increase in 2022. Additionally, long-term health and social care spending increased by 2.8% in real terms in 2022. Therefore, the rise in healthcare expenditure is contributing to the growth of the kinrix market.
In May 2024, GlaxoSmithKline plc, a UK-based pharmaceutical company, partnered with the Department of Health, Abu Dhabi (DoH), to establish a regional vaccine distribution hub in Abu Dhabi. This collaboration, formalized through a Memorandum of Understanding (MoU), aims to improve healthcare innovation and vaccine accessibility across the region. The Department of Health-Abu Dhabi (DoH) is a UAE-based government agency focused on promoting healthy living standards and raising awareness among the residents of the UAE.
The key company operating in the kinrix market is GlaxoSmithKline plc.
North America was the largest region in the kinrix market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in kinrix report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the kinrix market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Kinrix is a combination vaccine that offers protection against four diseases, diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis (polio). It includes diphtheria and tetanus toxoids, an acellular pertussis vaccine (DTaP), and an inactivated poliovirus vaccine (IPV). This vaccine streamlines vaccination schedules by reducing the number of injections needed, ensuring ongoing protection against these serious diseases in a convenient and efficient manner.
The primary types of indications for Kinrix include vaccination against diphtheria, tetanus, pertussis, and poliomyelitis. To protect against diphtheria, a toxoid vaccine is administered to stimulate immunity and prevent severe respiratory infections caused by Corynebacterium diphtheriae. The vaccine is available in injectable formulations and pre-filled syringes, suitable for both pediatric and adult patients. It is distributed through direct sales, wholesalers, distributors, retail pharmacies, and online pharmacies. Various end users, including pediatric clinics, hospitals, family practice clinics, and public health departments, utilize this vaccine.
The kinrix market research report is one of a series of new reports that provides kinrix market statistics, including kinrix industry global market size, regional shares, competitors with a kinrix market share, detailed kinrix market segments, market trends and opportunities, and any further data you may need to thrive in the kinrix industry. This kinrix market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The kinrix market consists of sales of pre-filled syringes or single-dose vials of kinrix (DTaP-IPV). Values in this market are ‘factory gate’ values, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Kinrix Market Characteristics4. Kinrix Market Trends and Strategies5. Kinrix Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Kinrix Pricing Analysis & Forecasts30. Global Kinrix Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Kinrix Market32. Recent Developments in the Kinrix Market
3. Kinrix Market Biologic Drug Characteristics
6. Global Kinrix Growth Analysis and Strategic Analysis Framework
8. Kinrix Market Segmentation
9. Global Kinrix Epidemiology of Clinical Indications
10. Kinrix Market Regional and Country Analysis
11. Asia-Pacific Kinrix Market
12. China Kinrix Market
13. India Kinrix Market
14. Japan Kinrix Market
15. Australia Kinrix Market
16. South Korea Kinrix Market
17. Western Europe Kinrix Market
18. UK Kinrix Market
19. Germany Kinrix Market
20. France Kinrix Market
21. Eastern Europe Kinrix Market
22. North America Kinrix Market
23. USA Kinrix Market
24. Canada Kinrix Market
25. South America Kinrix Market
26. Middle East Kinrix Market
27. Africa Kinrix Market
28. Kinrix Market Competitive Landscape and Company Profiles
29. Global Kinrix Market Pipeline Analysis
33. Kinrix Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Kinrix Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on kinrix market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for kinrix? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The kinrix market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Vaccination Against Diptheria; Vaccination Against Tetanus; Vaccination Against Pertussis; Vaccination Against Poliomyelitis2) by Formulation: Injectable Formulation; Pre-filled Syringes
3) by Patient Demographics: Pediatric; Adult
4) by Distribution Channel: Direct Sales; Wholesalers and Distributors; Retail Pharmacies; Online Pharmacies
5) by End Users: Pediatric Clinics; Hospitals; Family Practice Clinics; Public Health Departments
Key Companies Mentioned: GlaxoSmithKline plc
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- GlaxoSmithKline plc
